Drug Trial Radar · NCT07636772
A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma
Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Jun 22, 2026
Primary completion
Aug 24, 2028
Study completion Aug 24, 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.
Conditions
- Urothelial Carcinoma (UC)
Interventions
AK146D1 for injectionDrug
AK146D1 for injection is an antiTrop2/Nectin4 bispecific antibody-drug conjugate
AK112 InjectionDrug
AK112 Injection is a PD-1/VEGF bispecific antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose limiting toxicities(DLTs)Time frame: During the first 3 weeks of treatment
- Objective Response Rate(ORR)Time frame: Up to 2 years
- Number of participants with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.